Interchangeability of measurements of CA 19-9 in serum with four frequently used assays: An update

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 1, 2007, Pages 100-104

  Passerini, Rita ^a   Riggio, Daniela ^a   Salvatici, Michela ^a   Zorzino, Laura ^a   Radice, Davide ^a   Sandri, Maria Teresa ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Analytical performance; CA 19 9 determination; Comparability; Tumor marker

Indexed keywords

CA 19-9 ANTIGEN;

ACCURACY; ANALYTICAL EQUIPMENT; ARTICLE; ASSAY; FOLLOW UP; IMMUNOASSAY; INTERMETHOD COMPARISON; MEASUREMENT; PRIORITY JOURNAL; TUMOR;

BIOLOGICAL ASSAY; CA-19-9 ANTIGEN; HUMANS; IMMUNOENZYME TECHNIQUES; NEOPLASMS; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 33846516387     PISSN: 14346621     EISSN: 14346621     Source Type: Journal    
DOI: 10.1515/CCLM.2007.003     Document Type: Article

References (16)

1. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990;85:350-5.
2. Vestergaard EM, Hein HO, Meyer H, Grunnet N, Jorgensen J, Wolf H, et al. Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin Chem 1999;45:54-61.
3. Kim HJ, Kim MH, Myung SJ, Lim BC, Park ET, Yoo KS, et al. A new strategy for the application of CA 19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol 1999;94:1941-6.
4. Beretta E, Malesci A, Zerbi A, Mariani A, Carlucci M, Bonato C, et al. Serum CA 19-9 in the post surgical follow-up of patients with pancreatic cancer. Cancer 1987;60:2428-31.
5. Glenn J, Steinberg WM, Kurtzman SH, Steinberg SM, Sindelar WF. Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol 1988;6:462-8.
6. Ziske C, Schlie C, Gorschluter M, Glasmacher A, Mey U, Strehl J, et al. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 2003;89:1413-7.
7. Micke O, Bruns F, Kurowski R, Horst E, de Vries AF, Hausler JW, et al. Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy. Int J Radiat Oncol Biol Phys 2003;57:90-7.
8. Architect CA 19-9 List No. 6C04, Instruction manual. Abbott Laboratories, 1998.
9. AxSYM CA 19-9 List No. 7A50, Instruction manual. Abbott Laboratories, 2003.
10. Elecsys CA 19-9 Immunoassay List No 11776193, Instruction manual. Roche, 2004.
11. KRYPTOR CA 19-9 List No 807.100, Instruction manual. Brahms, 2004.
12. Tukey JW. Some thoughts on clinical trials, especially problems of multiplicity. Science 1977;198:679-84.
13. Passing H, Bablok W. A new biometrical procedure for testing the equality for measurement from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemestry, part I. J Clin Chem Clin Biochem 1983;21:709-20.
14. Krouwer JS, Monti KL. A simple, graphical method to evaluate laboratory assays. Eur J Clin Chem Clin Biochem 1995;33:525-7.
15. Wu JT, Chang J. Chromatographic characterization of CA 19-9 molecules from cystic fibrosis and pancreatic carcinoma. J Clin Lab Anal 1992;6:209-15.
16. Stern P, Friedecky B, Bartos V, Bezdckova D, Vavrova J, Uhrova J, et al. Comparison of different immunoassay for CA 19-9. Clin Chem Lab Med 2001;39:1278-82.